Risk factors in the progression of BK virus-associated nephropathy in renal transplant recipients.
10.3904/kjim.2015.30.6.865
- Author:
Hae Min LEE
1
;
In Ae JANG
;
Dongjae LEE
;
Eun Jin KANG
;
Bum Soon CHOI
;
Cheol Whee PARK
;
Yeong Jin CHOI
;
Chul Woo YANG
;
Yong Soo KIM
;
Byung Ha CHUNG
Author Information
1. Division of Nephrology, Department of Internal Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea. chungbh@catholic.ac.kr
- Publication Type:Original Article ; Research Support, Non-U.S. Gov't
- Keywords:
BK virus;
Kidney transplantation;
Nephropathy
- MeSH:
Adult;
Allografts;
Antiviral Agents/therapeutic use;
BK Virus/*pathogenicity;
Biomarkers/blood;
Biopsy;
Creatinine/blood;
Disease Progression;
Female;
Graft Rejection/diagnosis/drug therapy/immunology/*virology;
Graft Survival;
Humans;
Immunocompromised Host;
Immunosuppressive Agents/adverse effects;
Kaplan-Meier Estimate;
Kidney Transplantation/*adverse effects;
Male;
Middle Aged;
Opportunistic Infections/diagnosis/drug therapy/immunology/*virology;
Polyomavirus Infections/diagnosis/drug therapy/immunology/*virology;
Republic of Korea;
Retrospective Studies;
Risk Factors;
Time Factors;
Treatment Outcome;
Tumor Virus Infections/diagnosis/drug therapy/immunology/*virology
- From:The Korean Journal of Internal Medicine
2015;30(6):865-872
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND/AIMS: BK virus-associated nephropathy (BKVAN) is an important cause of allograft dysfunction in kidney transplant recipients. It has an unfavorable clinical course, and no definite treatment guidelines have yet been established. Here, we report our center's experience with biopsy-proven BKVAN and investigate factors associated with its progression. METHODS: From January 2004 to April 2013, 25 patients with BKVAN were diagnosed by biopsy at Seoul St. Mary's Hospital. Of the 25 patients, 10 were deceaseddonor transplant recipients and 15 were living-donor transplant recipients. Three of the patients underwent retransplantation. The primary immunosuppressant used was tacrolimus in 17 patients and cyclosporine in eight patients. RESULTS: BKVAN was observed at a mean duration of 22.8 ± 29.1 months after transplantation. The mean serum creatinine level at biopsy was 2.2 ± 0.7 mg/dL. BKVAN occurred with acute rejection in eight patients (28%). Immunosuppression modification was performed in 21 patients (84%). Additionally, leflunomide and intravenous immunoglobulin were administered to 13 patients (52%) and two (8%), respectively. Allograft loss occurred in five patients (27.8%) during the follow- up period at 0.7, 17.1, 21.8, 39.8, and 41.5 months after the BKVAN diagnosis. Advanced stages of BKVAN, increased creatinine levels, and accompanying acute rejection at the time of BKVAN diagnosis increased the risk of allograft failure. CONCLUSIONS: The clinical outcomes in patients with biopsy-proven BKVAN were unfavorable in the present study, especially in patients with advanced-stage BKVAN, poor renal function, and acute allograft rejection.
